Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Icu Medical (ICUI) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Icu Medical (ICUI) over the last 17 years, with Q3 2025 value amounting to $299.7 million.

  • Icu Medical's Cash & Equivalents fell 408.94% to $299.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $299.7 million, marking a year-over-year decrease of 408.94%. This contributed to the annual value of $308.6 million for FY2024, which is 2137.66% up from last year.
  • As of Q3 2025, Icu Medical's Cash & Equivalents stood at $299.7 million, which was down 408.94% from $300.0 million recorded in Q2 2025.
  • Icu Medical's Cash & Equivalents' 5-year high stood at $552.8 million during Q4 2021, with a 5-year trough of $195.9 million in Q2 2023.
  • Moreover, its 5-year median value for Cash & Equivalents was $299.7 million (2025), whereas its average is $312.1 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 6223.34% in 2022, then surged by 5848.11% in 2024.
  • Icu Medical's Cash & Equivalents (Quarter) stood at $552.8 million in 2021, then tumbled by 62.23% to $208.8 million in 2022, then grew by 21.76% to $254.2 million in 2023, then increased by 21.38% to $308.6 million in 2024, then dropped by 2.86% to $299.7 million in 2025.
  • Its Cash & Equivalents stands at $299.7 million for Q3 2025, versus $300.0 million for Q2 2025 and $289.7 million for Q1 2025.